This project has been flagged by a community member as inappropriate due to reason below.*

Survey

Slingshot members are conducting a survey! The topic is:

Quarterly Survey: Long-Read, Short-Read, and Hybrid DNA Sequencing Technology Usage and Preferences October 2023

Ticker(s): PACB, ILMN, TMO, BNGO

Who's being surveyed?

The survey includes 20 respondents currently using DNA technologies.

Survey Questions
Q1.

How would you best describe your practice?

  • Academic
  • Community
  • Commercial
  • Other

Q2.

Rank the factors that influence your choice of DNA sequencing technologies in your practice (where 1 is the most influential and 5 is least influential) Please rank all.

  • Accuracy
  • Cost
  • Ease of use
  • Read length
  • Throughput

Q3.

Do you use short-read sequencing technologies?

  • Yes
  • No

Q4.

What is the percentage breakdown of short-read sequencing technologies you currently use? /*Displayed if use short-read technology = yes*/

  • Illumina (e.g.,NovaSeq, HiSeq, MiSeq, etc.): 
  • Thermo Fisher Scientific (e.g., Ion Torrent, Ion GeneStudio, etc.): 
  • Oxford Nanopore Technologies (e.g., Flongle, Rapid Barcoding Kit): 
  • Other:

Q5.

What is the percentage breakdown of short-read sequencing technologies you expect to use in 1 year? /*Displayed if use short-read technology = yes*/

  • Illumina (e.g.,NovaSeq, HiSeq, MiSeq, etc.):
  • Thermo Fisher Scientific (e.g., Ion Torrent, Ion GeneStudio, etc.):
  • Oxford Nanopore Technologies (e.g., Flongle, Rapid Barcoding Kit):
  • Other:

Q6.

Please elaborate if you indicated "Other" above. If "Other" is 0, please indicate "NA". /*Displayed if use short-read technology = yes*/

Q7.

What are pros and cons of Illumina's short-read technologies? Please be specific. /*Displayed if use short-read technology = yes*/

Q8.

What are pros and cons of Thermo Fisher Scientific's short-read technologies? Please be specific. /*Displayed if use short-read technology = yes*/

Q9.

What are pros and cons of Oxford Nanopore's short-read technologies? Please be specific. /*Displayed if use short-read technology = yes*/

Q10.

Do you currently use long-read sequencing technologies?

  • Yes
  • No

Q11.

What is the percentage breakdown of long-read sequencing technologies you currently use? /*Displayed if use long-read technology = yes*/

  • PacBio (e.g., Sequel lle, RS II, etc.): 
  • Oxford Nanopore Technologies (e.g., MinION, GridION, PromethION, etc.): 
  • Bionano Genomics (e.g., Saphyr system): 
  • Other:

Q12.

What is the percentage breakdown of long-read sequencing technologies you expect to use in 1 year? /*Displayed if use long-read technology = yes*/

  • PacBio (e.g., Sequel lle, RS II, etc.):
  • Oxford Nanopore Technologies (e.g., MinION, GridION, PromethION, etc.):
  • Bionano Genomics (e.g., Saphyr system):
  • Other:

Q13.

Please elaborate if you indicated "Other" above. If "Other" is 0, please indicate "NA".  /*Displayed if use long-read technology = yes*/

Q14.

What are pros and cons of PacBio's long-read technologies? Please be specific.  /*Displayed if use long-read technology = yes*/

Q15.

What are pros and cons of Oxford Nanopore's long-read technologies? Please be specific.  /*Displayed if use long-read technology = yes*/

Q16.

What are pros and cons of Bionano Genomics' long-read technologies? Please be specific.  /*Displayed if use long-read technology = yes*/

Q17.

Do you currently use hybrid sequencing technologies?

  • Yes
  • No

Q18.

Why or why not?

Q19.

What is the most promising DNA sequencing technology in your opinion? Please be specific.

Q20.

What barriers, if any, have you noticed in adopting DNA sequencing technologies in your practice?

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.